Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (March 2019)
17 slides from Harrow's investor presentation, Mar 4, 2019
Slide 1: Harrow
HARROW NASDAQ: HROW MARCH 2019
Slide 2: Safe Harbor
HARROW SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward- looking statements. These statements are based on current expectations of future events. If underlyin
Slide 3: Harrow Health Introduction
Harrow Health Introduction ¢ Mitigate investment risk of drug development for the benefit of shareholders and patients VALUE CREATION + We found pharmaceutical companies + We finance them - We own: * large equity stakes, and * royalties on many of the drug candidates they develop
Slide 4: Risks of Drug Development
Harrow Health Introduction RISKS OF DRUG DEVELOPMENT ¢ How to find viable drug candidates? * Does the drug work? ¢ Is the drug safe? * Can it be manufactured to scale? ¢ What will it cost to complete clinical trials? Will doctors prescribe it? ¢ Will patients want to take it? ¢ What will they pay? ¢
Slide 5: Harrow Health Introduction
Harrow Health Introduction
Slide 6: MELT-100 Example
MELT-100* Example RISKS OF DRUG DEVELOPMENT * MELT-100 is a drug candidate for sedation and pain during cataract surgery. MELT-100 is being developed by Melt Pharmaceuticals, Inc., a company founded by Harrow Health, Inc. Does the drug work in humans? 611 patient IRB-approved study of compounded ver
Slide 7: Harrow Health Introduction
Harrow Health Introduction HARROW HEALTH INC. —————————— Deconsolidated businesses Royalty opportunities IMprimis p elon Eton's C1100 Pe Surface’s SURF-100 PARK Gu rface EES SURF-200, 201 Surface’s SURF-300, 301 MAYFIELD a Melt’s MELT-100** . MEET Mayfield’s MAY-66 8 a Mayfield’s MAY-88 Radley’s RAD
Slide 8: Financial Metrics
FINANCIAL METRICS HARROW
Slide 9: ImprimisRx Financials
ImprimisRx Financials TRENDS Revenue Growth: + ImprimisRx revenue grew >74% each quarter (Q1-Q3 2018) + 237% revenue CAGR 2014-2017 Gross Margins: + 2018 gross margins (Q3 - 61%) nearly 10% points higher than 2017 + Gross margin expansion expected in coming periods Profitablity: + Declining losses,
Slide 10: Harrow's Deconsolidated Equity Portfolio
Equity Portfolio HARROW’S DECONSOLIDATED EQUITY PORTFOLIO ESTIMATED VALUE: $56M* Melt $17,500,000 / 3.5M shares at $5 Eton $27,790,00 3.5M shares at $7.94 Surface 50,000 3.5M shares at $3.30 “Melt and Surface equity values are estimated and based on the conversion price of Series A preferred stock -
Slide 11: Royalty Rights Portfolio
Royalty Rights Portfolio DRUG PROPOSED MARKET ROYALTY CANDIDATE | INDICATION opportunity | CLINICAL STAGE | “pate INFANTILE SPASMS, $uB+ CT-100 RHEUMATIOID Neve PRE-CLINICAL 6% SRLS (Acthar’ Gel 17 sales!) $1.5B+ SURF-100 CHRONIC DRY EYE (Restasis’/ Xiidra* 17 eee IN 4% sales) $1B + (Comp: Kala EXPE
Slide 12: Summary
SUMMARY HARROW
Slide 13: Harrow Health Project
Harrow Health Project 15 Management incentivized to achieve $15 stock price * Operating business is fast growing and | Lest cash-flowing * Equity positions in deconsolidated businesses are now valued at ~$56M* (Non-GAAP) ¢ Future stream of royalties in diverse portfolio of drug development candidate
Slide 14: Appendix and References
APPENDIX AND REFERENCES HARROW
Slide 15: References
References 1, Harrow Health internal business data, including IMS data, 2015-2019, and proprietary surveys, 2015-2019 2. Centers for Disease Control and Prevention - United States. (2015, January). Retrieved February 27, 2019, from https://www.cdc.gov/ic/index.html
Slide 16: Published Clinical Data
Published Clinical Data Kindle, Trevor, MD, et al. (2018, January). Safety and efficacy of intravitreal injection of steroid and antibiotics in the setting of cataract surgery and trabecular microbypass stent. Journal of Cataract and Refractive Surgery. In a study of 483 eyes undergoing cataract sur
Slide 17: Harrow contact details
12264 EL CAMINO REAL, SUITE 350 HARROW | iss (858) 704-4040 H E A LT H ze IR@HARROWINC.COM WWW.HARROWINC.COM